Viewing data from:

SETLAKIN

ANDA

ETHINYL ESTRADIOL; LEVONORGESTREL | A090716 | NOVAST LABORATORIES LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: QUARTETTE(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Setlakin (2023)

Total Spending

$106K

Total Claims

1,735

Beneficiaries

592

Avg Cost/Unit

$0.67

Spending Trend

$114K(2019)→$144K(2020)→$142K(2021)→$120K(2022)→$106K(2023)

YoY Change:-9.6%

5yr CAGR:-3.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 0.03MG;0.15MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Sep 15, 2014

No patent or exclusivity listings for this strength.